Arts

Books

Fashion & Beauty

Performing Arts

Food

Visual Arts

Design

Business

Entrepreneurship

Investing

Marketing

Careers

Management

Non-Profit

Comedy

Stand-Up

Comedy Interviews

Improv

Education

Self-Improvement

How To

Courses

Language Learning

Fiction

Comedy Fiction

Drama

Science Fiction

Government

Health & Fitness

Medicine

Alternative Health

Nutrition

Mental Health

Fitness

Sexuality

History

Kids & Family

Parenting

Stories for Kids

Education for Kids

Pets & Animals

Leisure

Video Games

Games

Automotive

Animation & Manga

Hobbies

Aviation

Home & Garden

Crafts

Music

Music Commentary

Music Interviews

Music History

News

Sports News

Entertainment News

News Commentary

Politics

Daily News

Business News

Tech News

Religion & Spirituality

Christianity

Spirituality

Religion

Judaism

Islam

Buddhism

Hinduism

Science

Social Sciences

Life Sciences

Natural Sciences

Nature

Chemistry

Mathematics

Earth Sciences

Physics

Astronomy

Society & Culture

Documentary

Relationships

Philosophy

Personal Journals

Places & Travel

Sports

Golf

Soccer

Wrestling

Basketball

Football

Fantasy Sports

Baseball

Wilderness

Running

Hockey

Rugby

Cricket

Volleyball

Tennis

Swimming

Technology

True Crime

TV & Film

Film Interviews

TV Reviews

After Shows

Film Reviews

Film History

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

PeerView Internal Medicine CME/CNE/CPE Video Podcast

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

CancerCare's free Connect Education Workshops are a way for people to learn about cancer-related issues from the convenience of their home or office. Leading experts in oncology provide the most up-to-date information in these workshops to help you and your loved ones better understand and cope with your cancer diagnosis, treatment options, quality-of-life concerns, treatment side effects, pain management, doctor-patient communication and other important topics.

Kidney Cancer CancerCare Connect Education Workshops

Thyroid Cancer CancerCare Connect Education Workshops

MAC Tracks

Ovarian Cancer CancerCare Connect Education Workshops

Stories from Dr. Kwei Quartey about being both a crime writer and a physician

Leading A Double Life

Welcome to the Guild Dispensary, the pharmacy podcast where we dispense the latest news and updates from the Guild, and you get to hear from industry experts on business- and pharmacy-related topics.

Welcome to the Guild Dispensary, the pharmacy podcast where we dispense the latest news and updates from the Guild, and you get to hear from industry experts on business- and pharmacy-related topics.

The Guild Dispensary

Samitivej Podcast ย่อ ย่อย ยั่วสุขภาพให้เติมเต็มชีวิต กับสองสาวพิธีกรและคุณหมอจากโรงพยาบาลสมิติเวช
จัดเต็มเคล็ดลับ และทริคสุขภาพ ที่คุณไม่เคยฟังที่ไหน ฟังมันๆ มาฟังกันได้ที่  What the Health! ทุกพุธที่ 2 และ 4 ของเดือน

Samitivej Podcast ย่อ ย่อย ยั่วสุขภาพให้เติมเต็มชีวิต กับสองสาวพิธีกรและคุณหมอจากโรงพยาบาลสมิติเวช จัดเต็มเคล็ดลับ และทริคสุขภาพ ที่คุณไม่เคยฟังที่ไหน ฟังมันๆ มาฟังกันได้ที่ What the Health! ทุกพุธที่ 2 และ 4 ของเดือน

What the Health  เม้าท์ (สุขภาพ) กับหมอ

Exploring issues and challenges at the interface of the Christian faith and healthcare.

Exploring issues and challenges at the interface of the Christian faith and healthcare.

the CMF podcast

The first of its kind dentist-to-patient podcast, sharing valuable insight into the mouth-body connection.

Total Health Dentistry with Dr. Ali Farahani

On this podcast leading scientist, clinicians and entrepreneurs share their thoughts on the progress of personalized medicine. With our guests, we discuss new technologies for targeted treatments and diagnostics, their benefits for patients and clinicians and related implementation challenges.

Personalized Medicine Podcast

In this podcast series, the Global Resource for Advancing Cancer Education (GRACE) works to bring professionals together with patients and caregivers to work in partnership. We interview patients, advocates and healthcare professionals to provide the most updated information for our community and to highlight important issues facing those dealing with a cancer diagnosis. For more information visit www.cancerGRACE.org. To join the conversation, visit https://cancergrace.org/forums

In this podcast series, the Global Resource for Advancing Cancer Education (GRACE) works to bring professionals together with patients and caregivers to work in partnership. We interview patients, advocates and healthcare professionals to provide the most updated information for our community and to highlight important issues facing those dealing with a cancer diagnosis. For more information visit www.cancerGRACE.org. To join the conversation, visit https://cancergrace.org/forums

In this podcast series, the Global Resource for Advancing Cancer Education (GRACE) works to bring professionals together with patients and caregivers to work in partnership. We interview patients, advocates and healthcare professionals to provide the most updated information for our community and to highlight important issues facing those dealing with a cancer diagnosis. For more information visit www.cancerGRACE.org. To join the conversation, visit https://cancergrace.org/forums

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education

Emergency Medicine’s #1 Journal Publication: Clinical advances and trends from the most trusted emergency medical news source in emergency medicine.

Emergency Medicine News - Current Procalcitonin Utilization and Publications

The International Society of Nephrology (ISN) Podcast covers the diverse topics related to field of nephrology and the stories and experiences that impact the nephrologist around the world.

Global Kidney Care Podcast Provided by ISN

<div>A monthly podcast where editors of <a href="https://www.managedhealthcareexecutive.com/">Managed Healthcare Executive</a> chat with healthcare professionals and executives in the C-suite. 
 
 Each episode you will find a conversation about the most important issues facing American healthcare today: its cost, effectiveness, delivery and organization, and its fairness. 
 
Listen in. Learn a lot. 
 
For more information, visit us on <a href="https://www.facebook.com/ManagedHealthcareExecutive/">Facebook</a>, <a href="https://twitter.com/MHExecutive">Twitter</a> and <a href="https://www.linkedin.com/company/managed-healthcare-executive/">LinkedIn</a>. </div>

A monthly podcast where editors of Managed Healthcare Executive chat with healthcare professionals and executives in the C-suite. Each episode you will find a conversation about the most important issues facing American healthcare today: its cost, effectiveness, delivery and organization, and its fairness. Listen in. Learn a lot. For more information, visit us on Facebook, Twitter and LinkedIn.

A monthly podcast where editors of <a href="https://www.managedhealthcareexecutive.com/" rel="noopener noreferrer">Managed Healthcare Executive</a>&nbsp;chat with healthcare professionals and executives in the C-suite. 
 
 Each episode you will find a conversation about the most important issues facing American healthcare today: its cost, effectiveness, delivery and organization, and its fairness. 
 
Listen in. Learn a lot. 
 
For more information, visit us on <a href="https://www.facebook.com/ManagedHealthcareExecutive/" rel="noopener noreferrer">Facebook</a>, <a href="https://twitter.com/MHExecutive" rel="noopener noreferrer">Twitter</a> and <a href="https://www.linkedin.com/company/managed-healthcare-executive/" rel="noopener noreferrer">LinkedIn</a>.&nbsp;

Tuning In to The C-Suite

Physical Therapy and the ones that make it the profession that it is and what it’s going to be. How does one become a PT and what is done once you’re there? Let’s find out. Other health-related fields are here because we’re all interconnected.

Pre-PTs Talking PT

Join us as we go beyond the statistics to explore the human impact of one of the greatest health crises of our time. Over 350 million people are living with viral hepatitis worldwide. The Hep-cast is about the people whose lives have been changed by viral hepatitis and those fighting to eliminate it as a public health threat by 2030. Guests include people living with viral hepatitis, healthcare professionals, policymakers, and activists. They will expose the human cost of this cruel virus and explore what can be done to win the fight against it. The Hep-cast is a collaboration between the World Hepatitis Alliance and Gilead Sciences. The Hep-cast is fully funded by Gilead Sciences Europe Limited. <hr> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.

Join us as we go beyond the statistics to explore the human impact of one of the greatest health crises of our time. Over 350 million people are living with viral hepatitis worldwide. The Hep-cast is about the people whose lives have been changed by viral hepatitis and those fighting to eliminate it as a public health threat by 2030. Guests include people living with viral hepatitis, healthcare professionals, policymakers, and activists. They will expose the human cost of this cruel virus and explore what can be done to win the fight against it. The Hep-cast is a collaboration between the World Hepatitis Alliance and Gilead Sciences. The Hep-cast is fully funded by Gilead Sciences Europe Limited. Hosted on Acast. See acast.com/privacy for more information.

Join us as we go beyond the statistics to explore the human impact of one of the greatest health crises of our time. Over 350 million people are living with viral hepatitis worldwide. The Hep-cast is about the people whose lives have been changed by viral hepatitis and those fighting to eliminate it as a public health threat by 2030. Guests include people living with viral hepatitis, healthcare professionals, policymakers, and activists. They will expose the human cost of this cruel virus and explore what can be done to win the fight against it. The Hep-cast is a collaboration between the World Hepatitis Alliance and Gilead Sciences. The Hep-cast is fully funded by Gilead Sciences Europe Limited. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer">acast.com/privacy</a> for more information.

The Hep-cast

The respiratory therapy profession continues to grow. Through this podcast, industry leaders discuss how they're uniquely meeting the needs of patients and respiratory therapists.

The respiratory therapy profession continues to grow. Through this podcast, industry leaders discuss how they're uniquely meeting the needs of patients and respiratory therapists.

AARC Industry Insights

Welcome to DAP Talks, our weekly podcast program featuring all things DAP Health. Tune in to hear from our clinicians, public health team, and DAP leadership.

DAP Talks

<div>Welcome to Recovery Connections podcast.&nbsp;</div>This show provides information about helping you in substance abuse treatment. We know that this is not an easy process and there's a lot of differing information out there. And if we can give you our philosophy and the way we see the world out there, perhaps it wll be helpful to you or at least begin your process of seeking information and help. With host Michael Brier, CEO of Recovery Connection, and Greg Graustein, chief clinical director.For more info please visit <a href="http://www.drughelp.info" rel="noopener noreferrer" target="_blank">www.drughelp.info</a>&nbsp;or call 617-557-3155<div> </div>

Welcome to Recovery Connections podcast. This show provides information about helping you in substance abuse treatment. We know that this is not an easy process and there's a lot of differing information out there. And if we can give you our philosophy and the way we see the world out there, perhaps it wll be helpful to you or at least begin your process of seeking information and help. With host Michael Brier, CEO of Recovery Connection, and Greg Graustein, chief clinical director. For more info please visit www.drughelp.info or call 617-557-3155

Welcome to Recovery Connections podcast.&nbsp;This show provides information about helping you in substance abuse treatment. We know that this is not an easy process and there's a lot of differing information out there. And if we can give you our philosophy and the way we see the world out there, perhaps it wll be helpful to you or at least begin your process of seeking information and help. With host Michael Brier, CEO of Recovery Connection, and Greg Graustein, chief clinical director.For more info please visit <a href="http://www.drughelp.info" rel="noopener noreferrer">www.drughelp.info</a>&nbsp;or call 617-557-3155

Recovery Connection

Keep up to date with the latest literature and concepts in pediatric sports medicine. For orthopedists, trainers, and more!

Peds Sports

Welcome to the Petauri PACT Executive Briefing, where in 3-minutes we highlight healthcare’s critical market access issues, policies, challenges, or trends. This resource offers condensed, 3-minute episodes of market insights.&nbsp; Our passion is on achieving the Quintuple Aim of enhancing patient experience, improving population health, reducing costs, improving the work life of health care providers and staff., and enhancing health equity in all aspects of care delivery.&nbsp; I’m Dr. Warren Smedley, thank you for joining us.

Welcome to the Petauri PACT Executive Briefing, where in 3-minutes we highlight healthcare’s critical market access issues, policies, challenges, or trends. This resource offers condensed, 3-minute episodes of market insights.  Our passion is on achieving the Quintuple Aim of enhancing patient experience, improving population health, reducing costs, improving the work life of health care providers and staff., and enhancing health equity in all aspects of care delivery.  I’m Dr. Warren Smedley, thank you for joining us.

Petauri PACT Executive Briefings - 3-Minute Market Insights

One article.
One minute.
100% evidence based.
From the Washington University Hospital Medicine Virtual Journal Club
https://journalclub.wustl.edu/

One article. One minute. 100% evidence based. From the Washington University Hospital Medicine Virtual Journal Club https://journalclub.wustl.edu/

Hospital Medicine Virtual Journal Club Minute

What causes endometriosis? Why can endometriosis be so painful? Will there ever be a cure? This short podcast series seeks answers to some of the biggest questions posed by the endometriosis community.  

Danielle and Magda, PhD researchers at the University of Oxford, produce this podcast to raise endometriosis awareness and make the research done in the field accessible to everyone. They are especially keen on elevating the voices that often go unheard – the voices of people with endometriosis and early-career specialists & researchers in the field.

Tune in to learn more about endometriosis; a condition that affects 1 in 10 people born with a uterus.

What causes endometriosis? Why can endometriosis be so painful? Will there ever be a cure? This short podcast series seeks answers to some of the biggest questions posed by the endometriosis community. Danielle and Magda, PhD researchers at the University of Oxford, produce this podcast to raise endometriosis awareness and make the research done in the field accessible to everyone. They are especially keen on elevating the voices that often go unheard – the voices of people with endometriosis and early-career specialists & researchers in the field. Tune in to learn more about endometriosis; a condition that affects 1 in 10 people born with a uterus.

What causes endometriosis? Why can endometriosis be so painful? Will there ever be a cure? This short podcast series seeks answers to some of the biggest questions posed by the endometriosis community.  

Danielle and Magda, PhD researchers at the University of Oxford, produce this podcast to raise endometriosis awareness and make the research done in the field accessible to everyone. They are especially keen on elevating the voices that often go unheard – the voices of people with endometriosis and early-career specialists &amp; researchers in the field.

Tune in to learn more about endometriosis; a condition that affects 1 in 10 people born with a uterus.

Unheard of

A Slice of Healthcare podcast hosted by Nick Desai, Founder & FMR CEO of Heal. #healthcareservices #healthcaredelivery #politicsofhealthcare #healthcaretechnology

A Slice of Healthcare podcast hosted by Nick Desai, Founder &amp; FMR CEO of Heal. #healthcareservices #healthcaredelivery #politicsofhealthcare #healthcaretechnology

Nick's Notes

This podcast was created to better question healthcare and help locals in San Antonio make the best decisions to get back to their active lifestyle.

Positive Reaction Podcast

Email: medisfun2021@gmail.com 粉絲頁: https://www.facebook.com/medisfun2021 你們有沒有經驗過,從醫院整間走出來 聽不懂醫生剛剛在說什麼也不好意思問醫生 你們想要知道嗎 我會跟你們分享 順便回答你心中那一直沒機會問的的問題 希望你們可以一起瘋醫學 一起來起笑吧 Powered by <a href="https://firstory.me">Firstory Hosting</a>

Email: medisfun2021@gmail.com 粉絲頁: https://www.facebook.com/medisfun2021 你們有沒有經驗過,從醫院整間走出來 聽不懂醫生剛剛在說什麼也不好意思問醫生 你們想要知道嗎 我會跟你們分享 順便回答你心中那一直沒機會問的的問題 希望你們可以一起瘋醫學 一起來起笑吧 Powered by Firstory Hosting

Email: medisfun2021@gmail.com 粉絲頁: https://www.facebook.com/medisfun2021 你們有沒有經驗過,從醫院整間走出來 聽不懂醫生剛剛在說什麼也不好意思問醫生 你們想要知道嗎 我會跟你們分享 順便回答你心中那一直沒機會問的的問題 希望你們可以一起瘋醫學 一起來起笑吧 Powered by <a href="https://firstory.me" rel="noopener noreferrer">Firstory Hosting</a>

醫生也起笑

Charla semiformal de los aspectos sociales de la medicina.

Dr. Jorge Isaac Cardoza Encinas, Cirujano Ortopedista y aspirante a Locutor.
Axel Valdez, Diseñador Gráfico y Productor.

Charla semiformal de los aspectos sociales de la medicina. Dr. Jorge Isaac Cardoza Encinas, Cirujano Ortopedista y aspirante a Locutor. Axel Valdez, Diseñador Gráfico y Productor.

Ferulita para el Alma

LIFE Beyond Aphasia helps stroke survivors and care partners rebuild communication, confidence, and connection after formal rehab ends. 
Founded by Genevieve Richardson, M.S., CCC-SLP, this podcast bridges the gap between hospital discharge and living fully again. Viewers learn practical strategies to make progress at home, strengthen relationships, and feel like themselves again. 
Watch new episodes every week and start building your life beyond aphasia today.
Learn more at <a href="https://www.dolifespeechpathology.com/">https://www.dolifespeechpathology.com/</a>

LIFE Beyond Aphasia helps stroke survivors and care partners rebuild communication, confidence, and connection after formal rehab ends. Founded by Genevieve Richardson, M.S., CCC-SLP, this podcast bridges the gap between hospital discharge and living fully again. Viewers learn practical strategies to make progress at home, strengthen relationships, and feel like themselves again. Watch new episodes every week and start building your life beyond aphasia today. Learn more at https://www.dolifespeechpathology.com/

LIFE Beyond Aphasia helps stroke survivors and care partners rebuild communication, confidence, and connection after formal rehab ends. 
Founded by Genevieve Richardson, M.S., CCC-SLP, this podcast bridges the gap between hospital discharge and living fully again. Viewers learn practical strategies to make progress at home, strengthen relationships, and feel like themselves again. 
Watch new episodes every week and start building your life beyond aphasia today.
Learn more at <a href="https://www.dolifespeechpathology.com/" rel="noopener noreferrer">https://www.dolifespeechpathology.com/</a>&nbsp;

LIFE Beyond Aphasia

Approximately 34,000,000 people in the United States affected by type 2 diabetes. The Type 2 Diabetes Podcast aims to engage, educate, and empower listeners. Throughout this series, we will speak with medical experts, caregivers, and people living with the condition. 

Each episode will include references to useful resources available from our partners, trusted brands, and other reputable organizations. This podcast series will help listeners find answers to questions, access trustworthy information, and support them on their journey.

Visit healthunmuted.com for more information or contact the podcast team via email at hello@healthunmuted.com

Approximately 34,000,000 people in the United States affected by type 2 diabetes. The Type 2 Diabetes Podcast aims to engage, educate, and empower listeners. Throughout this series, we will speak with medical experts, caregivers, and people living with the condition. Each episode will include references to useful resources available from our partners, trusted brands, and other reputable organizations. This podcast series will help listeners find answers to questions, access trustworthy information, and support them on their journey. Visit healthunmuted.com for more information or contact the podcast team via email at hello@healthunmuted.com

Approximately 34,000,000 people in the United States affected by type 2 diabetes. The Type 2 Diabetes Podcast aims to engage, educate, and empower listeners. Throughout this series, we will speak with medical experts, caregivers, and people living with the condition.&nbsp;

Each episode will include references to useful resources available from our partners, trusted brands, and other reputable organizations. This podcast series will help listeners find answers to questions, access trustworthy information, and support them on their journey.

Visit healthunmuted.com for more information or contact the podcast team via email at hello@healthunmuted.com

Type 2 Diabetes Podcast

Accredited by the Wound, Ostomy, and Continence Nurses Society since 1976, the WOC Nursing Education Program prepares the graduate nurse to provide specialty care for patients with fecal and urinary incontinence. This program is geared towards the nurse looking to obtain WOCNB certification following the traditional pathway. The traditional pathway program is a blended education program. It is comprised of online clinical courses, onsite skills training (Bridge Week), a comprehensive final exam, and clinical with an approved preceptor. 

This podcast corresponds to the course video lectures and covers the topics below: 
- assessment for causative and contributing factors
- conservative management
- CIC, pelvic floor muscle rehabilitation, fluid and diet management, behavioral therapies (toileting program), absorptive and containment products

For more information on this program, please visit our website at www.wocnec.org.

Accredited by the Wound, Ostomy, and Continence Nurses Society since 1976, the WOC Nursing Education Program prepares the graduate nurse to provide specialty care for patients with fecal and urinary incontinence. This program is geared towards the nurse looking to obtain WOCNB certification following the traditional pathway. The traditional pathway program is a blended education program. It is comprised of online clinical courses, onsite skills training (Bridge Week), a comprehensive final exam, and clinical with an approved preceptor. This podcast corresponds to the course video lectures and covers the topics below: - assessment for causative and contributing factors - conservative management - CIC, pelvic floor muscle rehabilitation, fluid and diet management, behavioral therapies (toileting program), absorptive and containment products For more information on this program, please visit our website at www.wocnec.org.

Continence Management

Slowing aging by a couple of percent would save more money than curing any single disease, be it cancer, heart disease or diabetes. Aging is, in fact, the major risk factor that all these diseases have in common. For this reason, slowing aging becomes the most efficient path to a sustainable and healthy future for humanity.
To get this message out we started The Aging Science podcast. We will bring you interviews and frank conversations with leading experts in the field of longevity, as well as evidence-based health advice to support you on this journey.

Slowing aging by a couple of percent would save more money than curing any single disease, be it cancer, heart disease or diabetes. Aging is, in fact, the major risk factor that all these diseases have in common. For this reason, slowing aging becomes the most efficient path to a sustainable and healthy future for humanity. To get this message out we started The Aging Science podcast. We will bring you interviews and frank conversations with leading experts in the field of longevity, as well as evidence-based health advice to support you on this journey.

The Aging Science Podcast by VitaDAO

Welcome to the “Next Re-Generation Podcast” by the Osteology Foundation. We feature hot topics and novel perspectives - always with relevance to the dental career and practice. Join our hosts Anina and Elena and as they speak with new guests from around the world each month, and learn more about what’s important for the next generation in oral regeneration.

The Next ReGeneration Podcast

Parkinson's Disease: A Journey of Understanding, Hope, and Progress In the realm of neurodegenerative disorders, Parkinson's Disease (PD) stands as a formidable challenge, affecting millions of individuals worldwide. Named after Dr. James Parkinson, who first described the condition in 1817, PD is characterized by a constellation of motor symptoms, including tremors, stiffness, slowness of movement, and balance difficulties. These symptoms, which gradually rob individuals of their control over movement, arise from the loss of dopamine-producing neurons in the brain. As we delve into the complex world of PD, it becomes clear that this disease is far more than a simple movement disorder. It is a multifaceted condition that impacts not only the physical aspects of an individual's life but also their emotional, cognitive, and social well-being. The journey of understanding PD is one of unraveling the intricate interplay between the brain, the body, and the environment, and it is a journey that has been marked by significant advancements in recent years. At the heart of PD lies the pathophysiology of the disease, a complex web of cellular and molecular mechanisms that ultimately lead to the degeneration of dopaminergic neurons in the substantia nigra, a region of the midbrain. Dopamine, a neurotransmitter essential for regulating the brain's control of movement and coordination, is gradually depleted as these neurons die, giving rise to the hallmark motor symptoms of PD. But the story of PD's pathology does not end with the loss of dopamine. Researchers have discovered that the disease also involves the formation of abnormal aggregates of protein, primarily alpha-synuclein, within neurons. These aggregates, known as Lewy bodies, are a defining feature of PD, and their presence has sparked intense scientific interest. The exact causes of these protein aggregations and the subsequent neuronal death remain a mystery, with theories ranging from genetic mutations to environmental factors. As scientists work to unravel the complex etiology of PD, clinicians and patients alike are faced with the challenge of recognizing and addressing the early signs and symptoms of the disease. The onset of PD is typically insidious, with symptoms developing gradually over time. Early signs can be subtle, easily dismissed as the natural consequences of aging. Tremors, often starting in one hand and described as "pill-rolling," may be the first noticeable symptom. Bradykinesia, or slowness of movement, can make simple tasks like buttoning a shirt or tying shoelaces a time-consuming ordeal. Muscle rigidity, which can occur in any part of the body, may manifest as stiffness or a decreased range of motion. Impaired posture and balance, along with a loss of automatic movements like blinking or smiling, are also common early signs. But PD is not just a disease of movement. Non-motor symptoms, which often precede the onset of motor symptoms by several years, add another layer of complexity to the condition. Sleep disturbances, depression, anxiety, cognitive impairment, and autonomic dysfunction, such as constipation and blood pressure fluctuations, are all part of the PD experience. These non-motor symptoms can be just as debilitating as the motor symptoms, significantly impacting a person's quality of life. Diagnosing PD is a process of clinical acumen and exclusion, as there is no definitive laboratory test for the disease. Neurologists rely on their clinical examination skills and the patient's medical history to make a diagnosis, looking for the cardinal signs of PD and ruling out other conditions that may mimic its symptoms. Imaging studies, such as DAT-SPECT scans, which show reduced dopamine transporter activity in the brain, can support the diagnosis, but they are not definitive. Once a diagnosis of PD is made, the focus shifts to treatment and management. While there is currently no cure for PD, a range of treatments can help manage symptoms and improve quality of life. These treatments fall into three main categories: pharmacological, surgical, and non-pharmacological. Pharmacological treatments are the mainstay of PD management, with levodopa/carbidopa being the gold standard. Levodopa, a precursor to dopamine, is converted to dopamine in the brain, helping to replenish the depleted neurotransmitter. Carbidopa is added to prevent the premature conversion of levodopa to dopamine outside the brain, minimizing side effects. Other pharmacological options include dopamine agonists, which mimic the effects of dopamine; MAO-B inhibitors, which slow the breakdown of dopamine; COMT inhibitors, which prolong the action of levodopa; anticholinergics, which help reduce tremors and rigidity; and amantadine, which can provide symptomatic relief, particularly for levodopa-induced dyskinesias. Surgical treatments, such as deep brain stimulation (DBS), have emerged as a promising option for patients with advanced PD who respond poorly to medications. DBS involves implanting electrodes into specific areas of the brain and delivering electrical impulses to regulate abnormal brain activity. This technique has shown remarkable success in reducing motor symptoms and improving quality of life for many patients. Other surgical options, such as lesioning surgeries like pallidotomy and thalamotomy, are less common but may be considered in certain cases. Non-pharmacological treatments play a crucial role in the comprehensive management of PD. Physical therapy, with its focus on improving mobility, flexibility, and balance, can help patients maintain their physical function. Occupational therapy assists patients in managing daily activities and enhancing their quality of life through adaptive techniques and tools. Speech therapy addresses the speech and swallowing difficulties that are common in PD, helping patients maintain their ability to communicate and eat safely. Lifestyle modifications, including a healthy diet, stress management, and regular exercise, are also important components of PD management. In recent years, the landscape of PD research has been transformed by significant advancements in our understanding of the disease and the development of novel treatment approaches. Gene therapy, which involves delivering genes that can help restore dopamine production or protect neurons from degeneration, holds immense potential. Early clinical trials of AAV2-GDNF gene therapy have shown promise in providing neuroprotection and symptom relief. Stem cell therapy is another exciting area of research, with the goal of replacing lost dopaminergic neurons. Researchers are exploring the use of induced pluripotent stem cells (iPSCs) to generate dopamine-producing neurons for transplantation. Clinical trials are underway to assess the safety and efficacy of this approach, offering hope for a regenerative treatment for PD. Immunotherapy, which targets the abnormal aggregation of alpha-synuclein, is also showing promise. Vaccines and antibodies designed to clear or prevent the formation of these protein aggregates are being tested in clinical trials, with the potential to slow or halt the progression of PD. In addition to these cutting-edge therapies, new drug developments are expanding the treatment options for PD patients. NLY01, an experimental drug targeting neuroinflammation, has shown potential to slow disease progression in preclinical studies. Opicapone, a once-daily COMT inhibitor, enhances the effectiveness of levodopa and has been approved in some countries for managing motor fluctuations. Safinamide, a drug with dual mechanisms of action, provides additional symptom control for patients on levodopa therapy. Advances in DBS technology are also improving the precision and outcomes of this surgical treatment. Directional DBS leads allow for more targeted stimulation, reducing side effects and enhancing efficacy. Closed-loop DBS systems, which adjust stimulation in real-time based on brain activity, offer the promise of personalized and adaptive treatment. The role of gut microbiota in PD is an emerging area of research, with studies suggesting a link between gut microbial imbalances and the development and progression of the disease. Researchers are investigating whether modifying gut microbiota through diet, probiotics, or fecal transplants could offer therapeutic benefits for PD patients. Neuroprotective strategies, aimed at slowing or halting the progression of PD, are another active area of research. Molecules such as antioxidants, anti-inflammatory agents, and neurotrophic factors are being explored for their potential to protect neurons from degeneration. The calcium channel blocker isradipine, for example, has shown neuroprotective potential in preclinical studies and is currently being evaluated in clinical trials. Early diagnosis of PD is crucial for implementing neuroprotective strategies before significant neuronal loss occurs. Researchers are working to identify reliable biomarkers that can detect PD in its early stages, including imaging biomarkers, biochemical biomarkers in cerebrospinal fluid or blood, and genetic biomarkers. The role of lifestyle and environmental factors in PD development is also being actively investigated. Epidemiological studies have identified several factors that may influence PD risk, such as exposure to certain pesticides and herbicides, dietary habits, and exercise. Understanding the mechanisms by which these factors contribute to neurodegeneration could inform preventive strategies and targeted interventions. Clinical trials are the backbone of advancing PD treatment and research, providing valuable insights into the safety and efficacy of new therapies and refining existing ones. Patient involvement in these trials is essential for their success, and there are numerous ongoing trials invest

Parkinson's Disease: A Journey of Understanding, Hope, and Progress In the realm of neurodegenerative disorders, Parkinson's Disease (PD) stands as a formidable challenge, affecting millions of individuals worldwide. Named after Dr. James Parkinson, who first described the condition in 1817, PD is characterized by a constellation of motor symptoms, including tremors, stiffness, slowness of movement, and balance difficulties. These symptoms, which gradually rob individuals of their control over movement, arise from the loss of dopamine-producing neurons in the brain. As we delve into the complex world of PD, it becomes clear that this disease is far more than a simple movement disorder. It is a multifaceted condition that impacts not only the physical aspects of an individual's life but also their emotional, cognitive, and social well-being. The journey of understanding PD is one of unraveling the intricate interplay between the brain, the body, and the environment, and it is a journey that has been marked by significant advancements in recent years. At the heart of PD lies the pathophysiology of the disease, a complex web of cellular and molecular mechanisms that ultimately lead to the degeneration of dopaminergic neurons in the substantia nigra, a region of the midbrain. Dopamine, a neurotransmitter essential for regulating the brain's control of movement and coordination, is gradually depleted as these neurons die, giving rise to the hallmark motor symptoms of PD. But the story of PD's pathology does not end with the loss of dopamine. Researchers have discovered that the disease also involves the formation of abnormal aggregates of protein, primarily alpha-synuclein, within neurons. These aggregates, known as Lewy bodies, are a defining feature of PD, and their presence has sparked intense scientific interest. The exact causes of these protein aggregations and the subsequent neuronal death remain a mystery, with theories ranging from genetic mutations to environmental factors. As scientists work to unravel the complex etiology of PD, clinicians and patients alike are faced with the challenge of recognizing and addressing the early signs and symptoms of the disease. The onset of PD is typically insidious, with symptoms developing gradually over time. Early signs can be subtle, easily dismissed as the natural consequences of aging. Tremors, often starting in one hand and described as "pill-rolling," may be the first noticeable symptom. Bradykinesia, or slowness of movement, can make simple tasks like buttoning a shirt or tying shoelaces a time-consuming ordeal. Muscle rigidity, which can occur in any part of the body, may manifest as stiffness or a decreased range of motion. Impaired posture and balance, along with a loss of automatic movements like blinking or smiling, are also common early signs. But PD is not just a disease of movement. Non-motor symptoms, which often precede the onset of motor symptoms by several years, add another layer of complexity to the condition. Sleep disturbances, depression, anxiety, cognitive impairment, and autonomic dysfunction, such as constipation and blood pressure fluctuations, are all part of the PD experience. These non-motor symptoms can be just as debilitating as the motor symptoms, significantly impacting a person's quality of life. Diagnosing PD is a process of clinical acumen and exclusion, as there is no definitive laboratory test for the disease. Neurologists rely on their clinical examination skills and the patient's medical history to make a diagnosis, looking for the cardinal signs of PD and ruling out other conditions that may mimic its symptoms. Imaging studies, such as DAT-SPECT scans, which show reduced dopamine transporter activity in the brain, can support the diagnosis, but they are not definitive. Once a diagnosis of PD is made, the focus shifts to treatment and management. While there is currently no cure for PD, a range of treatments can help manage symptoms and improve quality of life. These treatments fall into three main categories: pharmacological, surgical, and non-pharmacological. Pharmacological treatments are the mainstay of PD management, with levodopa/carbidopa being the gold standard. Levodopa, a precursor to dopamine, is converted to dopamine in the brain, helping to replenish the depleted neurotransmitter. Carbidopa is added to prevent the premature conversion of levodopa to dopamine outside the brain, minimizing side effects. Other pharmacological options include dopamine agonists, which mimic the effects of dopamine; MAO-B inhibitors, which slow the breakdown of dopamine; COMT inhibitors, which prolong the action of levodopa; anticholinergics, which help reduce tremors and rigidity; and amantadine, which can provide symptomatic relief, particularly for levodopa-induced dyskinesias. Surgical treatments, such as deep brain stimulation (DBS), have emerged as a promising option for patients with advanced PD who respond poorly to medications. DBS involves implanting electrodes into specific areas of the brain and delivering electrical impulses to regulate abnormal brain activity. This technique has shown remarkable success in reducing motor symptoms and improving quality of life for many patients. Other surgical options, such as lesioning surgeries like pallidotomy and thalamotomy, are less common but may be considered in certain cases. Non-pharmacological treatments play a crucial role in the comprehensive management of PD. Physical therapy, with its focus on improving mobility, flexibility, and balance, can help patients maintain their physical function. Occupational therapy assists patients in managing daily activities and enhancing their quality of life through adaptive techniques and tools. Speech therapy addresses the speech and swallowing difficulties that are common in PD, helping patients maintain their ability to communicate and eat safely. Lifestyle modifications, including a healthy diet, stress management, and regular exercise, are also important components of PD management. In recent years, the landscape of PD research has been transformed by significant advancements in our understanding of the disease and the development of novel treatment approaches. Gene therapy, which involves delivering genes that can help restore dopamine production or protect neurons from degeneration, holds immense potential. Early clinical trials of AAV2-GDNF gene therapy have shown promise in providing neuroprotection and symptom relief. Stem cell therapy is another exciting area of research, with the goal of replacing lost dopaminergic neurons. Researchers are exploring the use of induced pluripotent stem cells (iPSCs) to generate dopamine-producing neurons for transplantation. Clinical trials are underway to assess the safety and efficacy of this approach, offering hope for a regenerative treatment for PD. Immunotherapy, which targets the abnormal aggregation of alpha-synuclein, is also showing promise. Vaccines and antibodies designed to clear or prevent the formation of these protein aggregates are being tested in clinical trials, with the potential to slow or halt the progression of PD. In addition to these cutting-edge therapies, new drug developments are expanding the treatment options for PD patients. NLY01, an experimental drug targeting neuroinflammation, has shown potential to slow disease progression in preclinical studies. Opicapone, a once-daily COMT inhibitor, enhances the effectiveness of levodopa and has been approved in some countries for managing motor fluctuations. Safinamide, a drug with dual mechanisms of action, provides additional symptom control for patients on levodopa therapy. Advances in DBS technology are also improving the precision and outcomes of this surgical treatment. Directional DBS leads allow for more targeted stimulation, reducing side effects and enhancing efficacy. Closed-loop DBS systems, which adjust stimulation in real-time based on brain activity, offer the promise of personalized and adaptive treatment. The role of gut microbiota in PD is an emerging area of research, with studies suggesting a link between gut microbial imbalances and the development and progression of the disease. Researchers are investigating whether modifying gut microbiota through diet, probiotics, or fecal transplants could offer therapeutic benefits for PD patients. Neuroprotective strategies, aimed at slowing or halting the progression of PD, are another active area of research. Molecules such as antioxidants, anti-inflammatory agents, and neurotrophic factors are being explored for their potential to protect neurons from degeneration. The calcium channel blocker isradipine, for example, has shown neuroprotective potential in preclinical studies and is currently being evaluated in clinical trials. Early diagnosis of PD is crucial for implementing neuroprotective strategies before significant neuronal loss occurs. Researchers are working to identify reliable biomarkers that can detect PD in its early stages, including imaging biomarkers, biochemical biomarkers in cerebrospinal fluid or blood, and genetic biomarkers. The role of lifestyle and environmental factors in PD development is also being actively investigated. Epidemiological studies have identified several factors that may influence PD risk, such as exposure to certain pesticides and herbicides, dietary habits, and exercise. Understanding the mechanisms by which these factors contribute to neurodegeneration could inform preventive strategies and targeted interventions. Clinical trials are the backbone of advancing PD treatment and research, providing valuable insights into the safety and efficacy of new therapies and refining existing ones. Patient involvement in these trials is essential for their success, and there are numerous ongoing trials invest

Parkinson's Disease: A Journey of Understanding, Hope, and Progress In the realm of neurodegenerative disorders, Parkinson's Disease (PD) stands as a formidable challenge, affecting millions of individuals worldwide. Named after Dr. James Parkinson, who first described the condition in 1817, PD is characterized by a constellation of motor symptoms, including tremors, stiffness, slowness of movement, and balance difficulties. These symptoms, which gradually rob individuals of their control over movement, arise from the loss of dopamine-producing neurons in the brain. As we delve into the complex world of PD, it becomes clear that this disease is far more than a simple movement disorder. It is a multifaceted condition that impacts not only the physical aspects of an individual's life but also their emotional, cognitive, and social well-being. The journey of understanding PD is one of unraveling the intricate interplay between the brain, the body, and the environment, and it is a journey that has been marked by significant advancements in recent years. At the heart of PD lies the pathophysiology of the disease, a complex web of cellular and molecular mechanisms that ultimately lead to the degeneration of dopaminergic neurons in the substantia nigra, a region of the midbrain. Dopamine, a neurotransmitter essential for regulating the brain's control of movement and coordination, is gradually depleted as these neurons die, giving rise to the hallmark motor symptoms of PD. But the story of PD's pathology does not end with the loss of dopamine. Researchers have discovered that the disease also involves the formation of abnormal aggregates of protein, primarily alpha-synuclein, within neurons. These aggregates, known as Lewy bodies, are a defining feature of PD, and their presence has sparked intense scientific interest. The exact causes of these protein aggregations and the subsequent neuronal death remain a mystery, with theories ranging from genetic mutations to environmental factors. As scientists work to unravel the complex etiology of PD, clinicians and patients alike are faced with the challenge of recognizing and addressing the early signs and symptoms of the disease. The onset of PD is typically insidious, with symptoms developing gradually over time. Early signs can be subtle, easily dismissed as the natural consequences of aging. Tremors, often starting in one hand and described as "pill-rolling," may be the first noticeable symptom. Bradykinesia, or slowness of movement, can make simple tasks like buttoning a shirt or tying shoelaces a time-consuming ordeal. Muscle rigidity, which can occur in any part of the body, may manifest as stiffness or a decreased range of motion. Impaired posture and balance, along with a loss of automatic movements like blinking or smiling, are also common early signs. But PD is not just a disease of movement. Non-motor symptoms, which often precede the onset of motor symptoms by several years, add another layer of complexity to the condition. Sleep disturbances, depression, anxiety, cognitive impairment, and autonomic dysfunction, such as constipation and blood pressure fluctuations, are all part of the PD experience. These non-motor symptoms can be just as debilitating as the motor symptoms, significantly impacting a person's quality of life. Diagnosing PD is a process of clinical acumen and exclusion, as there is no definitive laboratory test for the disease. Neurologists rely on their clinical examination skills and the patient's medical history to make a diagnosis, looking for the cardinal signs of PD and ruling out other conditions that may mimic its symptoms. Imaging studies, such as DAT-SPECT scans, which show reduced dopamine transporter activity in the brain, can support the diagnosis, but they are not definitive. Once a diagnosis of PD is made, the focus shifts to treatment and management. While there is currently no cure for PD, a range of treatments can help manage symptoms and improve quality of life. These treatments fall into three main categories: pharmacological, surgical, and non-pharmacological. Pharmacological treatments are the mainstay of PD management, with levodopa/carbidopa being the gold standard. Levodopa, a precursor to dopamine, is converted to dopamine in the brain, helping to replenish the depleted neurotransmitter. Carbidopa is added to prevent the premature conversion of levodopa to dopamine outside the brain, minimizing side effects. Other pharmacological options include dopamine agonists, which mimic the effects of dopamine; MAO-B inhibitors, which slow the breakdown of dopamine; COMT inhibitors, which prolong the action of levodopa; anticholinergics, which help reduce tremors and rigidity; and amantadine, which can provide symptomatic relief, particularly for levodopa-induced dyskinesias. Surgical treatments, such as deep brain stimulation (DBS), have emerged as a promising option for patients with advanced PD who respond poorly to medications. DBS involves implanting electrodes into specific areas of the brain and delivering electrical impulses to regulate abnormal brain activity. This technique has shown remarkable success in reducing motor symptoms and improving quality of life for many patients. Other surgical options, such as lesioning surgeries like pallidotomy and thalamotomy, are less common but may be considered in certain cases. Non-pharmacological treatments play a crucial role in the comprehensive management of PD. Physical therapy, with its focus on improving mobility, flexibility, and balance, can help patients maintain their physical function. Occupational therapy assists patients in managing daily activities and enhancing their quality of life through adaptive techniques and tools. Speech therapy addresses the speech and swallowing difficulties that are common in PD, helping patients maintain their ability to communicate and eat safely. Lifestyle modifications, including a healthy diet, stress management, and regular exercise, are also important components of PD management. In recent years, the landscape of PD research has been transformed by significant advancements in our understanding of the disease and the development of novel treatment approaches. Gene therapy, which involves delivering genes that can help restore dopamine production or protect neurons from degeneration, holds immense potential. Early clinical trials of AAV2-GDNF gene therapy have shown promise in providing neuroprotection and symptom relief. Stem cell therapy is another exciting area of research, with the goal of replacing lost dopaminergic neurons. Researchers are exploring the use of induced pluripotent stem cells (iPSCs) to generate dopamine-producing neurons for transplantation. Clinical trials are underway to assess the safety and efficacy of this approach, offering hope for a regenerative treatment for PD. Immunotherapy, which targets the abnormal aggregation of alpha-synuclein, is also showing promise. Vaccines and antibodies designed to clear or prevent the formation of these protein aggregates are being tested in clinical trials, with the potential to slow or halt the progression of PD. In addition to these cutting-edge therapies, new drug developments are expanding the treatment options for PD patients. NLY01, an experimental drug targeting neuroinflammation, has shown potential to slow disease progression in preclinical studies. Opicapone, a once-daily COMT inhibitor, enhances the effectiveness of levodopa and has been approved in some countries for managing motor fluctuations. Safinamide, a drug with dual mechanisms of action, provides additional symptom control for patients on levodopa therapy. Advances in DBS technology are also improving the precision and outcomes of this surgical treatment. Directional DBS leads allow for more targeted stimulation, reducing side effects and enhancing efficacy. Closed-loop DBS systems, which adjust stimulation in real-time based on brain activity, offer the promise of personalized and adaptive treatment. The role of gut microbiota in PD is an emerging area of research, with studies suggesting a link between gut microbial imbalances and the development and progression of the disease. Researchers are investigating whether modifying gut microbiota through diet, probiotics, or fecal transplants could offer therapeutic benefits for PD patients. Neuroprotective strategies, aimed at slowing or halting the progression of PD, are another active area of research. Molecules such as antioxidants, anti-inflammatory agents, and neurotrophic factors are being explored for their potential to protect neurons from degeneration. The calcium channel blocker isradipine, for example, has shown neuroprotective potential in preclinical studies and is currently being evaluated in clinical trials. Early diagnosis of PD is crucial for implementing neuroprotective strategies before significant neuronal loss occurs. Researchers are working to identify reliable biomarkers that can detect PD in its early stages, including imaging biomarkers, biochemical biomarkers in cerebrospinal fluid or blood, and genetic biomarkers. The role of lifestyle and environmental factors in PD development is also being actively investigated. Epidemiological studies have identified several factors that may influence PD risk, such as exposure to certain pesticides and herbicides, dietary habits, and exercise. Understanding the mechanisms by which these factors contribute to neurodegeneration could inform preventive strategies and targeted interventions. Clinical trials are the backbone of advancing PD treatment and research, providing valuable insights into the safety and efficacy of new therapies and refining existing ones. Patient involvement in these trials is essential for their success, and there are numerous ongoing trials invest

Medicine Podcasts / Page 101

PeerView Internal Medicine CME/CNE/CPE Video Podcast

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Kidney Cancer CancerCare Connect Education Workshops

Thyroid Cancer CancerCare Connect Education Workshops

MAC Tracks

Ovarian Cancer CancerCare Connect Education Workshops

Leading A Double Life

The Guild Dispensary

What the Health เม้าท์ (สุขภาพ) กับหมอ

the CMF podcast

Total Health Dentistry with Dr. Ali Farahani

Personalized Medicine Podcast

GRACEcast - Discussions with the Global Resource for Advancing Cancer Education

Emergency Medicine News - Current Procalcitonin Utilization and Publications

Global Kidney Care Podcast Provided by ISN

Tuning In to The C-Suite

Pre-PTs Talking PT

The Hep-cast

AARC Industry Insights

DAP Talks

Recovery Connection

Peds Sports

Petauri PACT Executive Briefings - 3-Minute Market Insights

Hospital Medicine Virtual Journal Club Minute

Unheard of

Nick's Notes

Positive Reaction Podcast

醫生也起笑

Ferulita para el Alma

LIFE Beyond Aphasia

Type 2 Diabetes Podcast

Continence Management

The Aging Science Podcast by VitaDAO

The Next ReGeneration Podcast

Parkinson’s Disease:

Pregúntale al Dr Paco Moreno

حكاوي الدكتورة لمى

Chapters of Life

The Invigor Medical Podcast

PH Insights

Following Science

Vitality Unleashed: The Functional Medicine Podcast

Single Mom MD

The Aesthetics Growth Podcast

The Hematology Podcast Series!

The Pain Management Toolbox

Opium: A History

《疗愈的饮食与断食》 | 杨定一著 张婉琦播（选读）

时常帮助

Decoding Sjogren’s Disease: A Clinical Deep Dive

《疗愈的饮食与断食》 | 杨定一著张婉琦播（选读）